echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > CSPC Lenvatinib Mesylate Capsules Approved for Marketing

    CSPC Lenvatinib Mesylate Capsules Approved for Marketing

    • Last Update: 2022-02-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On January 11, the official website of NMPA showed that CSPC's mitoxantrone hydrochloride liposome injection and lenvatinib mesylate capsules were approved for marketing


    Lenvatinib mesylate capsules is a multi-target receptor tyrosine kinase inhibitor developed by Eisai and Merck.


    The market size of lenvatinib mesylate capsules continued to rise after the launch


    Sales of Eisai Lenvatinib in China (unit: RMB million)

    Source: Sales Database of Multinational Listed Companies on Minet.


    With the approval of this product from CSPC, 8 local companies have been approved for production of lenvatinib mesylate capsules in the domestic market


    It is worth noting that there are currently 8 companies that have passed the evaluation of lenvatinib mesylate capsules, forming an 8+1 competition pattern, and they are likely to be included in the upcoming seventh batch of centralized procurement


    Note: The original text has been deleted

    Data source: Minet database, NMPA

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.